Cargando…
Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders
Concerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333079/ https://www.ncbi.nlm.nih.gov/pubmed/35905225 http://dx.doi.org/10.1097/MD.0000000000029571 |
_version_ | 1784758803694092288 |
---|---|
author | Marković, Ivan Božan, Marina Perković, Tomislav Paušek, Katarina Nedeljković, Vanja Perković, Marina Kelava, Tomislav Artuković, Marinko Stipić Marković, Asja |
author_facet | Marković, Ivan Božan, Marina Perković, Tomislav Paušek, Katarina Nedeljković, Vanja Perković, Marina Kelava, Tomislav Artuković, Marinko Stipić Marković, Asja |
author_sort | Marković, Ivan |
collection | PubMed |
description | Concerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate of immediate allergic reactions in patients with a history of drug allergy or other allergic disorders. We included adult patients who had received at least 1 dose of an mRNA COVID-19 vaccine at the Special Hospital for Pulmonary Diseases between March 1, 2021, and October 1, 2021, and who reported a history of drug allergy or other allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food or insect venom allergy, mastocytosis, idiopathic anaphylaxis, acute or chronic urticaria, and/or angioedema). Immediate allergic reactions, including anaphylaxis, occurring within 4 hours of vaccination were recorded. Six immediate allergic reactions were noted in the cohort of 1679 patients (0.36%). One patient experienced anaphylaxis (0.06%), which resolved after epinephrine administration, and the other reactions were mild and easily treatable. Most patients with a history of allergies can safely receive an mRNA COVID-19 vaccine, providing adequate observation periods and preparedness to recognize and treat anaphylaxis. |
format | Online Article Text |
id | pubmed-9333079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93330792022-08-03 Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders Marković, Ivan Božan, Marina Perković, Tomislav Paušek, Katarina Nedeljković, Vanja Perković, Marina Kelava, Tomislav Artuković, Marinko Stipić Marković, Asja Medicine (Baltimore) Research Article Concerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate of immediate allergic reactions in patients with a history of drug allergy or other allergic disorders. We included adult patients who had received at least 1 dose of an mRNA COVID-19 vaccine at the Special Hospital for Pulmonary Diseases between March 1, 2021, and October 1, 2021, and who reported a history of drug allergy or other allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food or insect venom allergy, mastocytosis, idiopathic anaphylaxis, acute or chronic urticaria, and/or angioedema). Immediate allergic reactions, including anaphylaxis, occurring within 4 hours of vaccination were recorded. Six immediate allergic reactions were noted in the cohort of 1679 patients (0.36%). One patient experienced anaphylaxis (0.06%), which resolved after epinephrine administration, and the other reactions were mild and easily treatable. Most patients with a history of allergies can safely receive an mRNA COVID-19 vaccine, providing adequate observation periods and preparedness to recognize and treat anaphylaxis. Lippincott Williams & Wilkins 2022-07-29 /pmc/articles/PMC9333079/ /pubmed/35905225 http://dx.doi.org/10.1097/MD.0000000000029571 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Marković, Ivan Božan, Marina Perković, Tomislav Paušek, Katarina Nedeljković, Vanja Perković, Marina Kelava, Tomislav Artuković, Marinko Stipić Marković, Asja Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title | Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title_full | Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title_fullStr | Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title_full_unstemmed | Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title_short | Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders |
title_sort | incidence of immediate allergic reactions to mrna covid-19 vaccines in adults with drug allergies and other allergic disorders |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333079/ https://www.ncbi.nlm.nih.gov/pubmed/35905225 http://dx.doi.org/10.1097/MD.0000000000029571 |
work_keys_str_mv | AT markovicivan incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT bozanmarina incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT perkovictomislav incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT pausekkatarina incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT nedeljkovicvanja incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT perkovicmarina incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT kelavatomislav incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT artukovicmarinko incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders AT stipicmarkovicasja incidenceofimmediateallergicreactionstomrnacovid19vaccinesinadultswithdrugallergiesandotherallergicdisorders |